Wednesday, Urigen Pharmaceuticals Inc. (URGP.OB) appointed William Schmidt to its Scientific Advisory Board. Schmidt, a pharmacologist, has been a consultant to Urigen since 2006 assisting with development strategy for URG101. His experience includes the development of Combunox, a combination pain product and other pain products.
Urigen Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products for urological disorders. Its products include URG101, which completed Phase II clinical trial for the treatment of painful bladder syndrome/interstitial cystitis in men and women; and URG301, a proprietary dosage form of an approved drug, which targets a female urethral suppository for urethritis and nocturia.
For comments and feedback: editorial@rttnews.com